Erythropoietin induced tumour mass reduction in murine lymphoproliferative models

Acta Haematologica

Volumn 114, Issue 3, 2005, Pages 177-179

  Katz, Odelia ^a   Barzilay, Eran ^a   Skaat, Alon ^a   Herman, Amir ^a   Mittelman, Moshe ^b   Neumann, Drorit ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOMODULATING AGENT; RECOMBINANT ERYTHROPOIETIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REMISSION; SURVIVAL; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; EPOETIN ALFA; FEMALE; LEUKEMIA, B-CELL; LYMPHOMA, B-CELL; LYMPHOPROLIFERATIVE DISORDERS; MICE; MICE, INBRED BALB C; PLASMACYTOMA;

EID: 27544504311     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000087896     Document Type: Article

References (13)

1. Henry DH, Bowers P, Romano MT, Provenzano R: Epoetin alfa. Clinical evolution of a pleiotropic cytokine. Arch Intern Med 2004;164:262-276.
2. Bieber E: Erythropoietin, the biology of erythropoiesis and epoetin alfa. An overview. J Reprod Med 2001;46:521-530.
3. Erslev AJ: Erythropoietin. Leuk Res 1990;14:683-688.
4. Spivak JL: Recombinant human erythropoietin and the anemia of cancer. Blood 1994;84:997-1004.
5. Mittelman M, Zeidman A, Fradin Z, Magazanik A, Lewinski UH, Cohen A: Recombinant human erythropoietin in the treatment of multiple myeloma-associated anemia. Acta Haematol 1997;98:204-210.
6. Mittelman M, Zeidman A, Kanter P, Katz O, Oster H, Rund D, Neumann D: Erythropoietin has an anti-myeloma effect - A hypothesis based on a clinical observation supported by animal studies. Eur J Haematol 2004;72:155-165.
7. Mittelman M, Neumann D, Peled A, Kanter P, Haran-Ghera N: Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proc Natl Acad Sci USA 2001;98:5181-5186.
8. Valeriote F, Grates H: MOPC-315 murine plasmacytoma as a model anticancer screen for human multiple myeloma. J Natl Cancer Inst 1986;76:61-65.
9. Slavin S, Weiss L, Morecki S, Bassat HB, Leizerowitz R, Gamliel H, Korkesh A, Voss R, Polliack A: Ultrastructural, cell membrane, and cytogenetic characteristics of B-cell leukemia, a murine model of chronic lymphocytic leukemia. Cancer Res 1981;41:4162-4166.
10. Strober S, Gronowicz ES, Knapp MR, Slavin S, Vitetta ES, Warnke RA, Kotzin B, Schroder J: Immunobiology of a spontaneous murine B cell leukemia (BCL1). Immunol Rev 1979;48:169-195.
11. Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C, Frommhold H: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-1260.
12. Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennett C, Engert A: Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 2005;97:489-498.
13. Littlewood TJ: Erythropoietin for the treatment of anemia associated with hematological malignancy. Hematol Oncol 2001;19:19-30.